Autologous Immune Enhancement Therapy (AIET) in Oncology
Publication on AIET | Frequently Asked Questions | Write up in Tamil | AIET more details | List of hospitals giving AIET
Cancer is still a leading cause of death in the world yet much is still not known about its mechanisms of establishment and destruction. While surgery and/or chemo- and radiotherapies have played key roles in treatment, it is clear that in many cases they do not represent a cure. Even when patients experience tumor regression, later relapse can occur. The need to address not only additional preventive measures, but also more effective and non-toxic treatment strategies are warranted. In the multipronged approach to CANCER, one very useful latest weapon would be AIET (Autologous Immune Enhancement Therapy), which is in clinical practice in Japan since 90s for more than 15 years with good effectiveness and several clinical trials and researches are reported from institutions all over the world including from the US, though there have not been any publications in this field from Indian Institutes or hospitals.
AIET is a treatment method in which some immune cells are taken out of a patient's body which are cultured and processed to be activated or to acquire additional functions until their resistance to cancer is strengthened, then the cells are put back in the body. The cells, antibodies, and organs of the immune system work to protect and defend the body against not only tumor cells but also foreign invaders, such as bacteria or viruses. Researchers have found that the thus activated immune system might also be able to determine the difference between healthy cells and cancer cells to eliminate the cancer cells from the body.
Upon encountering a tumor cell, the activated NK cell attaches to the membrane of the cancer cell and injects toxic granules that quickly dissolve the target cell. In less than five minutes, the cancer cell would be dead and the NK cell moves on to its next target. A single NK cell can destroy up to 27 cancer cells before it dies.
At present our protocol is based on reported clinical experiences from Japan and other developed nations, well accepted by the scientific community. Peripheral blood of the cancer patients (during remission in patients who undergo chemotherapy) is drawn and by proven methods, the peripheral blood mononuclear cells are separated. These cells are expanded in vitro during which they expand to 25-30 fold. Our processing technology specifically expands lymphocytes and NK cells to a significantly greater extent taking around 2-3 weeks. After expansion, the activated lymphocytes and NK cells are injected into the patient’s body wherein these cells act against the cancer cells effectively and also repopulate the patient’s peripheral blood cells thereby recharging the immune system.
For further details contact us at: info@ncrm.org
